细胞选择性分析揭示了II型激酶抑制剂的区别特征
Matthew J Binder1, Frances M Bashore1, Kaitlin K Dunn Hoffman2
1Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
使用基于细胞的测试来评估激酶抑制剂选择性,与无细胞测试提供了不同的结果. 这影响了化学探测器的优先级,并揭示了新的细胞激酶相互作用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 化学生物学 化学生物学
背景情况:
- 激酶抑制剂的开发需要严格的选择性评估.
- 从历史上看,无细胞检测一直是酶选择性分析的标准.
- 需要了解细胞环境如何影响抑制剂选择性.
研究的目的:
- 为了比较无细胞与基于细胞的试验中酶抑制剂选择性分析.
- 评估测试格式对化学探测器优先排序的影响.
- 为了识别特定于细胞环境的酶相互作用.
主要方法:
- 使用传统的无细胞检测分析对激酶抑制剂进行分析.
- 使用一个面板的细胞目标参与NanoBRET测定在完整的细胞.
- 从两种测试类型生成的选择性数据进行比较.
主要成果:
- 在无细胞和基于细胞的选择性分析数据之间观察到显著差异.
- 与无细胞数据相比,细胞分析影响了化学探针优先级.
- 在II型抑制剂的细胞中发现了意想不到的激酶相互作用,而在无细胞系统中没有发现这种相互作用.
结论:
- 细胞向参与试验在生理学上提供了更相关的评估,以评估酶抑制剂的选择性.
- 从无细胞检测转换为基于细胞的检测可以改变已识别的目标和目标之外的风景.
- 细胞测试对于发现特定环境的药物向相互作用和改进化学探针开发至关重要.
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K